Guest guest Posted November 3, 2005 Report Share Posted November 3, 2005 Hello Giora, Sorry you are unable ot attend the CML meeting in Genoa. Dr. Pierre Laneuville will be there to present his BCR ABL data. I will be seeing him on Monday and I will ask him if he can bring back material and information for us to make a summary of the meeting and post it to the group. I'll let you know what he says' Cheers, Cheryl-Anne > > next weekend there will be a top important cml conference in genoa italy. i am enclosing the program of the meeting so everyone can read the topics which cover every aspect of cml today and the names of all the leading drs that will attend and give presentations. the meeting is organized by ESH (european school of hematologists) . they have a web site which lists all their activities www.esh.org > since i thought it will be extremely important for cml patients to hear the presentations and the data which will be presented i applied to esh and asked to participate as a cml patient. they approved it and sent me the required forms. i sent them the registration with the 550 euros fees and made all flight and hotel arrangments. > sudenly yesterday i recieved an email from esh canceling my participation claiming that this meetings are open only for hematologists and scitists. i think it is a shame and no cml meeting should take place if there is no representation of us, the patients. > here is esh email to me > > Dear Sharf Giora > > Thank you for having contacted us about our upcoming ESH conference on > chronic myeloid leukaemia to take place in Genoa on November 11- 13, 2005. > > I hope that you will understand that we cannot register you for this meting > which is reserved for haematologists. Indeed, the European School of > Haematology is an institution for continuing education for clinical doctors > and scientists and we do not as yet have a branch devoted to the education > of patients. As soon as this question arises on our agenda, I will certainly > inform you. > > In the meantime, I congratulate you on the important work you are doing for > CML patients. > > Kind regards > > DiDi Jasmin > Executive Director, ESH > Centre Hayem > H?pital Saint-Louis > Paris 75010, France > Telephone : 33-1 42 06 65 40 > Fax: 33-1 42 06 05 87 > email : eshdi@c... > website : www.esh.org > > > i will do my best to use my connections and get the most important data from this meeting but it will not be the same. > here is the program > > > CML in the 21st Century > > > > > > 11-13 November 2005 - Genoa, Italy > > > > > > Principal organisers: A. Carella, J. Goldman > > Co-organisers: M. Baccarani, R. Hehlmann, F. Guilhot, N. Cross, A. Gewirtz, J. Melo > > > > . > > > > > > > > > > > > Friday, 11 November > > > > 08.30 PLENARY 1 Chairs: Goldman/Angelo Carella > > > > Lorenzo Pinna Protein kinases as `drugable' targets in malignant disease > > > > 09.15 PLENARY 2 Chairs: Angelo Carella/ Goldman > > > > Rick A van Etten Unravelling Abl > > > > > > 10.00 Session 1 – Molecular update > > Chairs: Alan Gewirtz, Giuseppe Saglio > > > > Junia Melo Regulation of the Bach2 transcription factor by Bcr-Abl > > > > Nick Cross Tyrosine kinases in CML and related disorders > > > > Giuseppe Saglio Induction of apoptosis as a targeted therapy for CML patients resistant to imatinib > > > > s Reiter FIP1L1-PDGFRA positive myeloproliferative syndrome > > > > Jim Development of AMN107, a novel second generation > > inhibitor of Bcr/Abl > > > > Nick Donato Targets and regulation of Lyn kinase in imatinib sensitive > > and resistant CML > > > > Alan Gewirtz Gene silencing strategies for the treatment of refractory CML > > > > Danilo Perrotti ReSETting PP2A tumor suppressor activity to antagonize BCR/ABL leukemogenic potential in blast crisis CML > > > > Jeroen Janssen Genes potentially involved in transformation of CML > > > > Enrica Lerma Gene profiling – what answers are possible? > > > > > > 14.00 Session 2 - Genomic instability > > Chairs: Skorski, Pierre Laneuville > > > > Wang Abl in the genotoxic response > > > > Tomas Skorski BCR/ABL regulates DNA damage and repair to induce > > imatinib resistance and genomic instability > > > > Carroll BCR/ABL Disrupts the response to DNA damage leading to chromosomal instability > > > > Bruno Calabretta Genetic and epigenetic changes during CML disease progression > > > > Pierre Laneuville Genomic instability in transgenic mouse models of bcr/abl > > expression > > > > Feyruz Rassool DNA damage and repair infidelity: a model for genomic instability in myeloid malignancies? > > > > > > 15.30 Session 3 – Stem cells and animal models > > Chairs: Junia Melo, Bayard son > > > > Ralph Arlinghaus Suppression of normal hematopoiesis by a modified form of neutrophil gelatinase-associated lipocalin (NGAL) derived from BCR-ABL-positive cells > > > > Bayard son Possible strategies for selectively killing Ph+ dormant stem cells > > > > Connie Eaves Genomic analysis of CML stem cells reveals an altered > > transcriptome and hidden mutants > > > > Mhairi Copland Targeting quiescent stem cells > > > > > > 16.30 Session 4 – BCR-ABL anD OTHER THERAPEUTIC TARGETS – PRECLINICAL > > Chairs: Nick Cross, Deininger > > > > von Bubnoff Prediction of resistance mutation patterns for novel Abl kinase > > inhibitors using a cell-based screening strategy > > > > Oliver Hantschel Structure-function analysis on Bcr-Abl > > > > Deininger BCR-ABL kinase domain mutations: beyond imatinib resistance > > > > Carlo Gambacorti Passerini Conformation dependent binding of SKI- 606 to Abl > > > > Shinya Kimura NS-187, a new dual Bcr- Abl/Lyn tyrosine kinase inhibitor > > > > Tim Br?mmendorf Imatinib plus hypusination inhibitors > > > > > > Saturday, 12 November > > > > 08.30 Session 5 – BCR-ABL AND OTHER THERAPEUTIC STRATEGIES - CLINICAL > > Chairs: Rudiger Hehlmann, Barrett > > > > Moshe Talpaz Dasatinib (BMS-354825) – Clinical results updated > > > > Cortes AMN107 – Clinical results updated > > > > Michele Baccarani Imatinib high dose and imatinib in combination with interferon > > > > Gert Ossenkoppele HOVON study of imatinib and cytarabine in first chronic phase CML > > > > Ute Berger Treatment intensification by combination therapies and dose > > escalation: The German CML-Study IV > > > > Francois Guilhot Rationale of combination of TK with Interferon or chemotherapy: > > Preliminary results of the French trials > > > > Cortes Farnesyl transferase inhibitors in CML: Still a role? > > > > > > 11.30 Session 6 – Immune mechanisms and immunotherapy > > Chairs: Michele Baccarani, Gale > > > > Barrett Immunotherapy strategies with or without allo-transplants > > > > Jeff Molldrem Unmasking self antigens as vaccine targets > > > > Scheinberg Specific immunotherapy of CML > > > > Bocchia P210-derived peptide vaccine for minimal residual disease > > in CML > > > > Evaluation of peptide immunization in CML (EPIC study) > > > > Hans Stauss TCR genes for the therapy of leukaemia > > > > > > 14.00 Session 7 – Molecular monitoring & Abl mutations > > Chairs: Tim , Neil Shah > > > > Tim Early predictors of response to ABL kinase inhibitors > > > > s Hochhaus Outcome of patients after detection of BCR- ABL mutations > > > > Marin Long-term BCR-ABL transcript patterns > > > > Neil Shah Not all Abl mutations are `equal' > > > > Simona Soverini ABL mutations and resistance to TK inhibitors > > > > Schiffer How should molecular and mutational analyses be used > > to advise patients with CML in chronic phase? > > > > 16.00 Session 8 – MOLECULAR STANDARDIZATION > > Chairs: s Hochhaus, Giovanni elli > > > > Goldman Standardisation – an international perspective > > > > Tim Towards international standardisation for MRD measurement > > in CML > > > > Giovanni elli Molecular standardization in monitoring in the era > > of dual TK inhibitors > > > > s Hochhaus European Proposal on Harmonization of PCR procedures > > > > > > > > > > Sunday, 13 November > > > > 08.30 Session 9 – Grafting strategies > > Chairs: Alois Gratwohl, Schiffer > > > > Agnes Devergie Allo-SCT in 5000 patients with CML in 1st CP – > > The European experience 1995- 2002 > > > > Jane Apperley Matched unrelated donor SCTs for CML-CP > > > > Alois Gratwohl Do we need allogeneic HSCT in the tyrosine kinase inhibitor era? > > > > Angelo Carella Long-term survival in CML patients after autografting/IFN-a > > and imatinib > > > > > > 11.00 Session 10 – Leukemia-Net & Guidelines > > Chair: Francois Guilhot, Silver > > > > Jorg Hasford Prognosis for CML patients treated with imatinib > > > > Pierre Laneuville Canadian Consensus Guidelines for CML > > > > R?diger Hehlmann Organization and highlights of the European LeukemiaNet > > > > Bengt Simonsson LeukemiaNet – Current progress > > > > 12.30 End of meeting > > > > > > i hope that we will be able to get the latest info from our drs and do something about future participation of patients in such meetings. > > shalom > > > > giora > > israel > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 3, 2005 Report Share Posted November 3, 2005 Hello Giora This should be a wonderful conference in Genoa, wish you could attend, but hopefully we will get some data and feedback. has consulted with three of the doctors presenting material, so we'll see what we can do too. Shalom Annette > > > > next weekend there will be a top important cml conference in genoa > italy. i am enclosing the program of the meeting so everyone can > read the topics which cover every aspect of cml today and the names > of all the leading drs that will attend and give presentations. the > meeting is organized by ESH (european school of hematologists) . > they have a web site which lists all their activities www.esh.org > > since i thought it will be extremely important for cml patients to > hear the presentations and the data which will be presented i > applied to esh and asked to participate as a cml patient. they > approved it and sent me the required forms. i sent them the > registration with the 550 euros fees and made all flight and hotel > arrangments. > > sudenly yesterday i recieved an email from esh canceling my > participation claiming that this meetings are open only for > hematologists and scitists. i think it is a shame and no cml meeting > should take place if there is no representation of us, the patients. > > here is esh email to me > > > > Dear Sharf Giora > > > > Thank you for having contacted us about our upcoming ESH > conference on > > chronic myeloid leukaemia to take place in Genoa on November 11- > 13, 2005. > > > > I hope that you will understand that we cannot register you for > this meting > > which is reserved for haematologists. Indeed, the European School > of > > Haematology is an institution for continuing education for > clinical doctors > > and scientists and we do not as yet have a branch devoted to the > education > > of patients. As soon as this question arises on our agenda, I will > certainly > > inform you. > > > > In the meantime, I congratulate you on the important work you are > doing for > > CML patients. > > > > Kind regards > > > > DiDi Jasmin > > Executive Director, ESH > > Centre Hayem > > H?pital Saint-Louis > > Paris 75010, France > > Telephone : 33-1 42 06 65 40 > > Fax: 33-1 42 06 05 87 > > email : eshdi@c... > > website : www.esh.org > > > > > > i will do my best to use my connections and get the most important > data from this meeting but it will not be the same. > > here is the program > > > > > > CML in the 21st Century > > > > > > > > > > > > 11-13 November 2005 - Genoa, Italy > > > > > > > > > > > > Principal organisers: A. Carella, J. Goldman > > > > Co-organisers: M. Baccarani, R. Hehlmann, F. Guilhot, N. Cross, A. > Gewirtz, J. Melo > > > > > > > > . > > > > > > > > > > > > > > > > > > > > > > > > Friday, 11 November > > > > > > > > 08.30 PLENARY 1 > Chairs: Goldman/Angelo Carella > > > > > > > > Lorenzo Pinna Protein kinases as `drugable' targets in > malignant disease > > > > > > > > 09.15 PLENARY 2 Chairs: Angelo > Carella/ Goldman > > > > > > > > Rick A van Etten Unravelling Abl > > > > > > > > > > > > 10.00 Session 1 – Molecular update > > > > Chairs: Alan Gewirtz, Giuseppe Saglio > > > > > > > > Junia Melo Regulation of the Bach2 transcription > factor by Bcr-Abl > > > > > > > > Nick Cross Tyrosine kinases in CML and related > disorders > > > > > > > > Giuseppe Saglio Induction of apoptosis as a targeted > therapy for CML patients resistant to imatinib > > > > > > > > s Reiter FIP1L1-PDGFRA positive > myeloproliferative syndrome > > > > > > > > Jim Development of AMN107, a novel > second generation > > > > inhibitor of Bcr/Abl > > > > > > > > Nick Donato Targets and regulation of Lyn kinase in > imatinib sensitive > > > > and resistant CML > > > > > > > > Alan Gewirtz Gene silencing strategies for the > treatment of refractory CML > > > > > > > > Danilo Perrotti ReSETting PP2A tumor suppressor > activity to antagonize BCR/ABL leukemogenic potential in blast > crisis CML > > > > > > > > Jeroen Janssen Genes potentially involved in > transformation of CML > > > > > > > > Enrica Lerma Gene profiling – what answers are > possible? > > > > > > > > > > > > 14.00 Session 2 - Genomic instability > > > > Chairs: Skorski, Pierre Laneuville > > > > > > > > Wang Abl in the genotoxic response > > > > > > > > Tomas Skorski BCR/ABL regulates DNA damage and repair > to induce > > > > imatinib resistance and genomic > instability > > > > > > > > Carroll BCR/ABL Disrupts the response to DNA > damage leading to > chromosomal instability > > > > > > > > Bruno Calabretta Genetic and epigenetic changes during CML > disease > progression > > > > > > > > Pierre Laneuville Genomic instability in transgenic mouse > models of bcr/abl > > > > expression > > > > > > > > Feyruz Rassool DNA damage and repair infidelity: a model > for genomic instability in myeloid malignancies? > > > > > > > > > > > > 15.30 Session 3 – Stem cells and animal models > > > > Chairs: Junia Melo, Bayard son > > > > > > > > Ralph Arlinghaus Suppression of normal hematopoiesis by a > modified form of neutrophil gelatinase-associated lipocalin (NGAL) > derived from BCR-ABL-positive cells > > > > > > > > Bayard son Possible strategies for selectively > killing Ph+ dormant stem cells > > > > > > > > Connie Eaves Genomic analysis of CML stem cells > reveals an altered > > > > transcriptome and hidden mutants > > > > > > > > Mhairi Copland Targeting > quiescent stem cells > > > > > > > > > > > > 16.30 Session 4 – BCR-ABL anD OTHER THERAPEUTIC > TARGETS – PRECLINICAL > > > > Chairs: Nick Cross, Deininger > > > > > > > > von Bubnoff Prediction of resistance mutation patterns > for novel Abl kinase > > > > inhibitors using a cell-based screening strategy > > > > > > > > Oliver Hantschel Structure-function analysis on Bcr-Abl > > > > > > > > Deininger BCR-ABL kinase domain mutations: beyond > imatinib resistance > > > > > > > > Carlo Gambacorti Passerini Conformation dependent binding of SKI- > 606 to Abl > > > > > > > > Shinya Kimura NS-187, a new dual Bcr- > Abl/Lyn tyrosine kinase inhibitor > > > > > > > > Tim Br?mmendorf Imatinib plus hypusination inhibitors > > > > > > > > > > > > Saturday, 12 November > > > > > > > > 08.30 Session 5 – BCR-ABL AND OTHER THERAPEUTIC > STRATEGIES - CLINICAL > > > > Chairs: Rudiger Hehlmann, Barrett > > > > > > > > Moshe Talpaz Dasatinib (BMS-354825) – Clinical results > updated > > > > > > > > Cortes AMN107 – Clinical results updated > > > > > > > > Michele Baccarani Imatinib high dose and imatinib in > combination with interferon > > > > > > > > Gert Ossenkoppele HOVON study of imatinib and cytarabine in > first chronic phase CML > > > > > > > > Ute Berger Treatment intensification by > combination therapies and dose > > > > > escalation: The German CML-Study IV > > > > > > > > Francois Guilhot Rationale of combination of TK with > Interferon or chemotherapy: > > > > Preliminary results of the French trials > > > > > > > > Cortes Farnesyl transferase inhibitors in CML: > Still a role? > > > > > > > > > > > > 11.30 Session 6 – Immune mechanisms > and immunotherapy > > > > Chairs: Michele Baccarani, Gale > > > > > > > > Barrett Immunotherapy strategies with or > without allo-transplants > > > > > > > > Jeff Molldrem Unmasking self > antigens as vaccine targets > > > > > > > > Scheinberg Specific immunotherapy of CML > > > > > > > > Bocchia P210-derived peptide vaccine for minimal > residual disease > > > > in CML > > > > > > > > Evaluation of peptide immunization in > CML (EPIC study) > > > > > > > > Hans Stauss TCR genes for the therapy of > leukaemia > > > > > > > > > > > > 14.00 Session 7 – Molecular monitoring & Abl > mutations > > > > Chairs: Tim , Neil Shah > > > > > > > > Tim Early predictors of response to ABL > kinase inhibitors > > > > > > > > s Hochhaus Outcome of patients after detection of BCR- > ABL mutations > > > > > > > > Marin Long-term BCR-ABL transcript patterns > > > > > > > > Neil Shah Not all Abl mutations are `equal' > > > > > > > > Simona Soverini ABL mutations and resistance to TK > inhibitors > > > > > > > > Schiffer How should molecular and mutational > analyses be used > > > > to advise patients with CML in chronic > phase? > > > > > > > > 16.00 Session 8 – MOLECULAR STANDARDIZATION > > > > Chairs: s Hochhaus, Giovanni elli > > > > > > > > Goldman Standardisation – an international > perspective > > > > > > > > Tim Towards international > standardisation for MRD measurement > > > > in CML > > > > > > > > Giovanni elli Molecular standardization in > monitoring in the era > > > > of dual TK inhibitors > > > > > > > > s Hochhaus European Proposal on Harmonization of PCR > procedures > > > > > > > > > > > > > > > > > > > > > Sunday, 13 November > > > > > > > > 08.30 Session 9 – Grafting strategies > > > > Chairs: Alois Gratwohl, Schiffer > > > > > > > > Agnes Devergie Allo-SCT in 5000 patients with CML in 1st > CP – > > > > The European experience 1995- > 2002 > > > > > > > > Jane Apperley Matched unrelated donor SCTs for CML-CP > > > > > > > > Alois Gratwohl Do we need allogeneic HSCT in the > tyrosine kinase inhibitor era? > > > > > > > > Angelo Carella Long-term survival in CML patients after > autografting/IFN-a > > > > and imatinib > > > > > > > > > > > > 11.00 Session 10 – Leukemia-Net & Guidelines > > > > Chair: Francois Guilhot, Silver > > > > > > > > Jorg Hasford Prognosis for > CML patients treated with imatinib > > > > > > > > Pierre Laneuville Canadian > Consensus Guidelines for CML > > > > > > > > > R?diger Hehlmann Organization and highlights of the European > LeukemiaNet > > > > > > > > Bengt Simonsson LeukemiaNet – Current progress > > > > > > > > > 12.30 > End of meeting > > > > > > > > > > > > i hope that we will be able to get the latest info from our drs > and do something about future participation of patients in such > meetings. > > > > shalom > > > > > > > > giora > > > > israel > > > > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.